Many studies have reported the value of different tumor markers in the diagnosis of HCC, but there is currently no study using PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations for the differential diagnosis of primary and metastatic HCC. This evidence concerns the gene AFP and hepatocellular carcinoma.